Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories Lei ChengWei RenXiao-Ping Qian Review Article 11 June 2014 Pages: 1 - 13
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors Hiroshi WakuiNoboru YamamotoTomohide Tamura Original Article 22 April 2014 Pages: 15 - 23
Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent Ying Yi ChenPradeep B. LukkaBruce C. Baguley Original Article 07 May 2014 Pages: 25 - 35
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC) Hidehito HorinouchiNoboru YamamotoTomohide Tamura Original Article 08 May 2014 Pages: 37 - 43
Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans Eleftheria TsakalozouEyob D. AdaneMarkos Leggas Original Article 08 May 2014 Pages: 45 - 54
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib Hao XiongYi-Lin ChiuPatricia LoRusso Original Article 09 May 2014 Pages: 55 - 61
Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers Markus ZollingerFrédéric Lozac’hPiet Swart Original Article 10 May 2014 Pages: 63 - 75
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma Devalingam MahalingamLaeeq MalikJohn Sarantopoulos Original Article 10 May 2014 Pages: 77 - 84
Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia Ali-Akbar GolabchifarSaeed RezaeeMohammad-Reza Rouini Original Article 10 May 2014 Pages: 85 - 93
Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics Yi GuJian WangWeiguo Su Original Article 11 May 2014 Pages: 95 - 115
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors Autumn J. McReeJanine M. DaviesBert H. O’Neil Original Article 13 May 2014 Pages: 117 - 123
Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors Johanna C. BendellDavid S. HongRazelle Kurzrock Original Article 13 May 2014 Pages: 125 - 130
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer Patricia RoxburghGraeme R. LumsdenAlexander C. McDonald Original Article 13 May 2014 Pages: 131 - 139
Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer Marine JaryFrancois GhiringhelliStefano Kim Original Article 14 May 2014 Pages: 141 - 150
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide Wendi V. RodriguezaMichael J. WoolliscroftAyad Al-Katib Original Article Open access 16 May 2014 Pages: 151 - 166
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells Han MinMin XuXiao-ping Zou Original Article 20 May 2014 Pages: 167 - 176
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501) Rathi N. PillaiJoseph AisnerJoan H. Schiller Original Article 24 May 2014 Pages: 177 - 183
Irinotecan and temozolomide brain distribution: a focus on ABCB1 Lauriane GoldwirtKevin BeccariaChristine Fernandez Original Article 28 May 2014 Pages: 185 - 193
Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors Monica MitaMichael GordonAnthony W. Tolcher Clinical Trial Report 22 May 2014 Pages: 195 - 204
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer Yixing JiangHeath B. MackleyChandra P. Belani Clinical Trial Report 08 June 2014 Pages: 205 - 210
High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin Oscar ArrietaLuis-Alberto MedinaJaime de la Garza-Salazar Short Communication 10 May 2014 Pages: 211 - 215